Last update 06 Jul 2026

Shanghai Regenelead Therapies Co., Ltd.

Startups
| Private Company | Subsidiary Company|2021|Shanghai Shi, China

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Nervous System Diseases
Therapeutic vaccine
mRNA vaccine
mRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease3
Nervous System Diseases2
Neoplasms2
Immune System Diseases1
Top 5 Drug TypeCount
Biological products2
Therapeutic vaccine2
AAV based gene therapy2
mRNA1
mRNA vaccine1
Top 5 TargetCount
KRAS G12C x KRAS G12D x KRAS G12V x KRAS G13D1
DDC x GDNF family1

Related

7
Drugs associated with Shanghai Regenelead Therapies Co., Ltd.
RGL-2102
Target-
Mechanism-
Active Org.
Shanghai Regenelead Therapies Co., Ltd.
Originator Org.
Shanghai Regenelead Therapies Co., Ltd.
Active Indication
Diabetic foot ulcer [+3]
Inactive Indication-
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
HRXG-K-1939
Target-
Mechanism
Immunostimulants
Active Org.
Shanghai Regenelead Therapies Co., Ltd.
 [+3]
Originator Org.
Shanghai Regenelead Therapies Co., Ltd.
Active Indication
Non-Small Cell Lung Cancer [+7]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
RGL-2201
Target-
Mechanism-
Active Org.
Shanghai Regenelead Therapies Co., Ltd.
Originator Org.
Shanghai Regenelead Therapies Co., Ltd.
Active Indication
Choroidal Neovascularization [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
22
Clinical Trials associated with Shanghai Regenelead Therapies Co., Ltd.
CTR20260513
/ RecruitingPhase 1
评价个性化新抗原mRNA疫苗RGL-270联合阿得贝利单抗在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征、免疫原性及初步有效性的开放标签、多中心I期临床研究
[Translation] An open-label, multicenter phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy of the personalized neoantigen mRNA vaccine RGL-270 in combination with adebelimab in patients with advanced malignant solid tumors.
ChiCTR2600118847
/ SuspendedPhase 2IIT
Evaluation of the Efficacy and Safety of Injectable RGL-2102 in Patients with Severe Lower Limb Ischemia: A Randomized, Double-Blind, Parallel-Group Phase Ⅱ Clinical Trial
ChiCTR2500115334
/ SuspendedPhase 1IIT
An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability and immunogenicity of RGL-232 in patients with advanced malignant solid tumors carrying KRAS mutations
100 Clinical Results associated with Shanghai Regenelead Therapies Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Regenelead Therapies Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Regenelead Therapies Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Regenelead Therapies Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
1
IND Approval
Phase 1
4
1
Phase 2
Phase 3
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free